98%
921
2 minutes
20
Background: Cervical cancer has high morbidity and intratumor heterogeneity. Anoikis, a form of programmed cell death preventing detached cancer cells from readhering, may serve as a potential prognostic signature for cervical cancer. This study aimed to assess the predictive performance of anoikis patterns in cervical cancer prognosis.
Methods: Differentially expressed anoikis-related genes (DEARGs) were identified between normal and cancer samples using data from the Gene Expression Omnibus database with the elucidation of mutation status and bio-function. Novel anoikis molecular subtypes were defined in The Cancer Genome Atlas (TCGA) cohort with consensus clustering analysis. A multigene prognostic signature was constructed through least absolute shrinkage and selection operator (LASSO) Cox analysis with internal and external validation. The nomogram-based survival probability of cervical cancer over 3 and 5 years was predicted and assessed with calibration, receiver operating characteristic, decision curve analysis, and Kaplan-Meier curves. Additionally, mutation, function, and immune analysis were conducted among different risk groups.
Results: We identified 77 DEARGs between normal and cervical cancer tissues and explored their mutation status and functions. The TCGA cohort could be categorized into two subtypes based on these genes. Furthermore, seven prognostic signature genes were constructed, and the nomogram involving DEARGs and clinicopathological characteristics showed satisfactory predictive performance. Functional analysis indicated that immune-related genes were enriched, and immune status, as well as sensitivity of chemotherapies and targeting drugs, were correlated with the risk model.
Conclusions: Anoikis patterns play important roles in tumor immunity and can be used to predict the prognosis of cervical cancers.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.31083/j.fbl2811287 | DOI Listing |
Nat Med
September 2025
Emerging Technology, Research Prioritization and Support Unit, Department of Research for Health, World Health Organization, Geneva, Switzerland.
Clinical trials are essential to advancing cancer control, yet access and participation remain unequal globally. The World Health Organization (WHO) established the International Clinical Trials Registry Platform (ICTRP) to enable a complete view of interventional clinical research for all those involved in healthcare decision-making and to identify actionable goals to equitable participation at the global level. A review of 89,069 global cancer clinical trials registered in the WHO ICTRP between 1999 and December 2022 revealed a cancer clinical trial landscape dominated by high-income countries and focused on pharmacological interventions, with multinational collaboration limited to only 3% of recruiting trials.
View Article and Find Full Text PDFWomens Health Issues
September 2025
Tufts University School of Medicine/Tufts Medicine, Boston, Massachusetts. Electronic address:
Background: More than 20% of cervical cancers are diagnosed in women older than 65 years. Guidelines recommend screening exit at age 65 for average-risk patients only if certain criteria are met, yet most women aged 64-66 years in the United States are inadequately screened. In this mixed methods study, we explored clinician knowledge of exit criteria.
View Article and Find Full Text PDFObjectives: Cervical cancer is a serious threat to women's life and health and has a high mortality rate. Colposcopy is an important method for early clinical cervical cancer screening, but the traditional vaginal dilator has problems such as discomfort in use and cumbersome operation. For this reason, this study aims to design an intelligent vaginal dilatation system to automate colposcopy and enhance patient comfort.
View Article and Find Full Text PDFJMIR Res Protoc
September 2025
Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Background: Cancer screening nonadherence persists among adults who are deaf, deafblind, and hard of hearing (DDBHH). These barriers span individual, clinician, and health care system levels, contributing to difficulties understanding cancer information, accessing screening services, and following treatment directives. Critical communication barriers include ineffective patient-physician communication, limited access to American Sign Language (ASL) cancer information, misconceptions about medical procedures, insurance navigation difficulties, and intersectional barriers for multiply marginalized individuals.
View Article and Find Full Text PDFOral Oncol
September 2025
Department of Oral Mucosa, Shanghai Stomatological Hospital & School of Stomatology, Fudan University, Shanghai, China; Shanghai Key Laboratory of Craniomaxillofacial Development and Diseases, Fudan University, Shanghai, China. Electronic address: